Real Patient Stories

Pictures of real Emgality patients with episodic migraine

Real stories of migraine-free days with Emgality1

Hear from real patients with episodic migraine (4-14 migraine headache days [MHDs] per month)1a

View efficacy results in patients with episodic migraine

aPatients were compensated for their time.

Meet Lisa in Emgality bubble with play button

Lisa, a traveler with migraine

Lisa has had episodic migraine for over 33 years.

Meet Bonnie in Emgality bubble with play button

Bonnie, a food enthusiast with migraine

Bonnie has had episodic migraine for nearly 15 years.

Tally Up calendar with stickers in Emgality bubble

Tally Up helps empower patients to track and celebrate migraine-free days

The Tally Up Journal is a place where your patients can track migraine-free days. Patients also have Information Cards that they may share with friends who are interested in learning about Emgality.

You can request the Tally Up Journal by calling the Emgality Answers Center at 1-833-EMGALITY (1-833-364-2548).

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Start your patients on Emgality today. View savings carda and additional resources.

aGovernmental beneficiaries excluded; terms and conditions apply.

References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.